KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Cash from Financing Activities (2016 - 2025)

Novavax has reported Cash from Financing Activities over the past 16 years, most recently at -$6.6 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at -$6.6 million for Q4 2025, down 92.99% from a year ago — trailing twelve months through Dec 2025 was $27.7 million (down 89.36% YoY), and the annual figure for FY2025 was $27.7 million, down 89.36%.
  • Cash from Financing Activities for Q4 2025 was -$6.6 million at Novavax, down from $42.4 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for NVAX hit a ceiling of $577.0 million in Q1 2021 and a floor of -$354.4 million in Q1 2023.
  • Median Cash from Financing Activities over the past 5 years was $2.3 million (2022), compared with a mean of $54.0 million.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 321.67% in 2023 and later skyrocketed 43854.64% in 2025.
  • Novavax's Cash from Financing Activities stood at -$60.7 million in 2021, then skyrocketed by 415.33% to $191.4 million in 2022, then tumbled by 47.56% to $100.4 million in 2023, then plummeted by 103.41% to -$3.4 million in 2024, then plummeted by 92.99% to -$6.6 million in 2025.
  • The last three reported values for Cash from Financing Activities were -$6.6 million (Q4 2025), $42.4 million (Q3 2025), and -$1.0 million (Q2 2025) per Business Quant data.